Selective elimination of host cells harboring replication-competent human immunodeficiency virus reservoirs: a promising therapeutic strategy for HIV cure.
10.1097/CM9.0000000000001797
- Author:
Silvere D ZAONGO
1
;
Yue WANG
2
,
3
;
Ping MA
4
;
Fang-Zhou SONG
5
;
Yao-Kai CHEN
1
Author Information
1. Division of Infectious Diseases, Chongqing Public Health Medical Center, Chongqing 400036, China.
2. Institute for Medical Device Standardization Administration
3. National Institutes for Food and Drug Control, Beijing 100050, China.
4. Department of Infectious Diseases, Tianjin Second People Hospital, Tianjin 300192, China.
5. College of Basic Medicine, Chongqing Medical University, Chongqing 400016, China.
- Publication Type:Journal Article
- MeSH:
CD4-Positive T-Lymphocytes;
HIV Infections/drug therapy*;
HIV-1;
Humans;
Virus Latency
- From:
Chinese Medical Journal
2021;134(23):2776-2787
- CountryChina
- Language:English
-
Abstract:
Many seminal advances have been made in human immunodeficiency virus (HIV)/AIDS research over the past four decades. Treatment strategies, such as gene therapy and immunotherapy, are yielding promising results to effectively control HIV infection. Despite this, a cure for HIV/AIDS is not envisioned in the near future. A recently published academic study has raised awareness regarding a promising alternative therapeutic option for HIV/AIDS, referred to as "selective elimination of host cells capable of producing HIV" (SECH). Similar to the "shock and kill strategy," the SECH approach requires the simultaneous administration of drugs targeting key mechanisms in specific cells to efficiently eliminate HIV replication-competent cellular reservoirs. Herein, we comprehensively review the specific mechanisms targeted by the SECH strategy. Briefly, the suggested cocktail of drugs should contain (i) latency reversal agents to promote the latency reversal process in replication-competent reservoir cells, (ii) pro-apoptotic and anti-autophagy drugs to induce death of infected cells through various pathways, and finally (iii) drugs that eliminate new cycles of infection by prevention of HIV attachment to host cells, and by HIV integrase inhibitor drugs. Finally, we discuss three major challenges that are likely to restrict the application of the SECH strategy in HIV/AIDS patients.
